Neuronetics SEC Filings

Neuronetics, Inc. (STIM) reported an insider equity award. On 10/20/2025, a director acquired 7,326 shares of common stock at $0, coded “A,” under the company’s non-employee director compensation plan. The award reflects an election to receive stock in lieu of a cash retainer, delivered as restricted stock units that vested immediately upon grant, with each RSU equal to one share.

Following the transaction, the director beneficially owned 221,716 shares, held directly.

Neuronetics, Inc. (STIM) reported an insider equity award by a director. On 10/20/2025, the director acquired 7,554 shares of common stock via a restricted stock unit (RSU) grant at $0 under the non-employee directors compensation plan, electing stock in lieu of a cash retainer.

The RSU award vested immediately upon grant, with each RSU representing one share. Following the transaction, the director’s beneficial ownership stands at 371,816 shares, held directly.

Neuronetics, Inc. (STIM) reported an insider transaction by a director. On 10/20/2025, the director acquired 6,410 shares of common stock via a restricted stock unit (RSU) grant that vested immediately and was elected in lieu of a cash retainer under the non-employee directors compensation plan. The RSU acquisition price was $0, with each RSU representing one share.

Following the transaction, the director beneficially owned 1,512,798 shares directly. The filing also lists indirect beneficial ownership of 516,084 shares through Greybrook Health Inc. and 2,042 shares through Greybrook Realty Partners Inc.

Madryn and affiliated funds report beneficial ownership of 20,737,061 shares of Neuronetics, Inc. common stock, representing approximately 31.4% of the outstanding shares based on 66,124,820 shares outstanding as of July 31, 2025. The Schedule 13D/A amends a prior filing and consolidates holdings across multiple Madryn entities and advisers while clarifying that Madryn and the advisors may be deemed to have indirect beneficial ownership through their advisory and partnership roles.

The amendment also discloses executed sales: MHP II, MHP II Cayman and MSO sold specified tranches of shares under Rule 144 at about $3.72 per share, and it notes that Covered Persons generally disclaim beneficial ownership except that Avinash Amin holds 12,500 shares (<1%) directly.

Neuronetics, Inc. (STIM) filed a Form 144 reporting a proposed sale of 2,925,554 common shares, with an aggregate market value of $10,883,060.88. The filing lists Morgan Stanley Smith Barney LLC as the broker and indicates the shares are to be sold on NASDAQ with an approximate sale date of 08/08/2025.

The notice shows the shares were acquired on 12/10/2024 in connection with a Merger/Acquisition from the issuer and were paid for in cash. The filer reports nothing to report for securities sold in the past three months and includes the standard representation that they are not aware of any undisclosed material adverse information about the issuer.

Neuronetics, Inc. (STIM) filed a Form 144 reporting a proposed sale of 192,806 common shares with an aggregate market value of $717,238.32. The filing states the sale is expected on or about 08/08/2025 on NASDAQ and lists Morgan Stanley Smith Barney LLC as the broker. The shares were acquired on 12/10/2024 in a merger/acquisition transaction from the issuer and were paid for in cash. The filing reports 66,124,820 shares outstanding and notes Nothing to Report for sales in the past three months.

Neuronetics, Inc. (Form 144) filed a notice proposing the sale of 381,640 shares of Common stock through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 08/08/2025 and an aggregate market value of $1,419,700.80 against 66,124,820 shares outstanding. The shares to be sold were acquired from the issuer in a merger/acquisition on 12/10/2024.

The filing shows the purchase was paid in cash on 12/10/2024, reports no securities sold in the past three months, and includes the required signer representation that the seller is not aware of undisclosed material adverse information about the issuer. The notice identifies the executing broker and the exchange but provides no further financial results or forward guidance.